TrialInternational journal of chronic obstructive pulmonary disease2014

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Andrea Koch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.